This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Fuh is an ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Among men worldwide, prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. As the world's population ages, the number of prostate cancer patients is expected ...

Multigene next-generation sequencing (NGS) performed directly on tumor tissue can accurately identify pathogenic variants in epithelial ovarian cancer (EOC), detecting both somatic and germline ...

Gray hair is an inevitable hallmark of aging. It's a visual reminder of the passing years and all the bodily changes that ...

The ICGEC-2 conference on cancer genetics and epigenetics, featuring AI-based approaches, launched at JSS Medical College, ...

The same cell product could potentially be used to treat multiple solid tumors like ovarian, pancreatic and lung cancers.

Breast cancer detection has evolved from microscopes to molecular precision to offer diagnostic insights: Expert: Shardul Nautiyal, Mumbai Saturday, November 1, 2025, 08:00 Hrs [I ...

The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

Myriad Genetics ( ($MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.